Published in N Engl J Med on October 10, 1974
Deanol in tardive dyskinesia. Br Med J (1975) 0.78
Orofacial dyskinesia. Clinical features, mechanisms and drug therapy. West J Med (1976) 0.76
Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology (1999) 2.64
Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry (2001) 2.06
Allelic variation in the DR subregion of the human major histocompatibility complex. Proc Natl Acad Sci U S A (1987) 1.92
Subtractive hybridization system using single-stranded phagemids with directional inserts. Nucleic Acids Res (1990) 1.58
Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol (1987) 1.56
The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med (1993) 1.50
Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res (2001) 1.21
Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry (1991) 1.14
Telemetered EEG-EOG during psychotic behaviors of schizophrenia. Arch Gen Psychiatry (1979) 1.14
Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes (Lond) (2005) 1.09
Tardive dyskinesia. Acta Psychiatr Scand (1988) 1.07
Pharmacology of blepharospasm-oromandibular dystonia syndrome. Neurology (1980) 0.99
Sulpiride in tardive dyskinesia. Psychopharmacology (Berl) (1979) 0.99
Psychiatric patients on medical wards. I. Prevalence of illness and recognition of disorders by staff personnel. Arch Gen Psychiatry (1966) 0.98
Corticotropin release during ECT in man. Am J Psychiatry (1974) 0.97
Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry (1983) 0.94
Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. Gen Hosp Psychiatry (1992) 0.94
Levodopa and receptor sensitivity modification in tardive dyskinesia. Psychopharmacology (Berl) (1982) 0.92
Control of severe agitation with droperidol. Dis Nerv Syst (1972) 0.92
The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist. Arch Gen Psychiatry (1982) 0.90
Orientation specificity of visual cortical neurons after head tilt. Exp Brain Res (1972) 0.88
gamma-Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry (1980) 0.88
Molecular mapping of class II polymorphisms in the human major histocompatibility complex. I. DR beta. J Immunol (1987) 0.87
The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand (1993) 0.86
Pharmacological characterization of tardive dyskinesia. Psychopharmacology (Berl) (1977) 0.86
Effect of gamma-vinyl GABA in tardive dyskinesia. Psychiatry Res (1983) 0.86
Molecular mapping class II polymorphisms in the human major histocompatibility complex. II. DQ beta. J Immunol (1987) 0.85
Amantadine intoxication reversed by physostigmine. N Engl J Med (1978) 0.84
A cross-cultural study of reactivation of posttraumatic stress disorder symptoms: American and Cambodian psychophysiological response to viewing traumatic video scenes. J Nerv Ment Dis (1998) 0.84
Movements in never-medicated schizophrenics: a preliminary study. Psychopharmacology (Berl) (1996) 0.84
The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry (1991) 0.83
Thermal effects on response of cat touch corpuscle. Exp Neurol (1970) 0.83
Tardive dyskinesia: reversible and irreversible. Psychopharmacology Suppl (1985) 0.83
Tardive dyskinesia in the aged. Duration of treatment relationships. Arch Gen Psychiatry (1985) 0.83
Tardive dyskinesia: are there subtypes. N Engl J Med (1976) 0.82
Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates. Psychopharmacology (Berl) (1999) 0.82
Responses of cortical neurones to stimulation of the visual afferent radiations. Exp Brain Res (1968) 0.82
Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res (1989) 0.81
Dose response of prophylactic antipsychotics. J Clin Psychiatry (1993) 0.80
Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens, and medial prefrontal cortex. Psychopharmacology (Berl) (1992) 0.80
Sulpiride in tardive dyskinesia. Acta Psychiatr Scand Suppl (1984) 0.80
Kindling with clozapine: behavioral and molecular consequences. Epilepsy Res (1996) 0.79
Spontaneous and tardive dyskinesias: clinical and laboratory studies. J Clin Psychiatry (1985) 0.79
An objective method for measuring dyskinetic movements in tardive dyskinesia. Electroencephalogr Clin Neurophysiol (1975) 0.78
The eye blink electro-oculogram. Br J Ophthalmol (1984) 0.78
Tardive dyskinesia as a life-threatening illness. Am J Psychiatry (1978) 0.78
Sodium valproate in tardive dyskinesia. J Clin Psychiatry (1979) 0.78
Tardive dyskinesia and diabetes mellitus. Psychopharmacol Bull (1992) 0.78
Neuroleptic-induced parkinsonism in older schizophrenics. Biol Psychiatry (1987) 0.78
Three-year follow-up of older schizophrenics: extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio. Biol Psychiatry (1991) 0.78
Ten-year outcome of tardive dyskinesia. Am J Psychiatry (1994) 0.77
Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacol Bull (1989) 0.77
Neuroleptic intolerance. Schizophr Bull (1997) 0.77
Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse. Neuroscience (2010) 0.77
Oxiperomide in tardive dyskinesia. J Neurol Neurosurg Psychiatry (1980) 0.77
Tardive dyskinesia status: stability or change. Psychopharmacol Bull (1988) 0.77
The differential diagnosis of tardive dyskinesia. Acta Psychiatr Scand Suppl (1981) 0.77
Behavioral effects of long-term neuroleptic treatment in Cebus monkeys. Psychopharmacology Suppl (1985) 0.77
Effect of des-tyrosine-gamma-endorphin in tardive dyskinesia. Arch Gen Psychiatry (1981) 0.77
Effects of benztropine on ketamine-induced behaviors in Cebus monkeys. Behav Pharmacol (2001) 0.76
High-dose destyrosine-gamma-endorphin in tardive dyskinesia. Psychopharmacology (Berl) (1982) 0.76
Dopamine, acetylcholine, and GABA effects in acute dystonia in primates. Psychopharmacology (Berl) (1980) 0.76
Design and fabrication of an experimental cochlear prosthesis. Med Biol Eng Comput (1983) 0.76
Enkephalin, morphine, and naloxone in tardive dyskinesia. Psychopharmacology (Berl) (1980) 0.76
Sensitization with clozapine: beyond the dopamine hypothesis. Biol Psychiatry (1997) 0.75
Mood alterations during deanol therapy. Psychopharmacology (Berl) (1979) 0.75
Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drug-related parkinsonism. Psychopharmacology (Berl) (1984) 0.75
Actual versus self-reported intake and exercise in obesity. N Engl J Med (1993) 0.75
Neuroleptic-induced parkinsonism increases with repeated treatment in monkeys. Psychopharmacol Ser (1987) 0.75
Recurrent pneumonitis due to Pseudomonas cepacia. An unexpected phagocyte dysfunction. West J Med (1975) 0.75
Health insurance reform and the physician-patient relationship. JAMA (1993) 0.75
Treatment of fractures of the maxilla and mandible. Surg Clin North Am (1968) 0.75
Effects of calcium infusion on urinary hydroxyproline and phosphorus: evaluation as a diagnostic test. J Clin Endocrinol Metab (1966) 0.75
Coadministration of haloperidol and SCH-23390 prevents the increase in "perforated" synapses due to either drug alone. Neuropsychopharmacology (1992) 0.75
Sulpiride and oxiperomide in tardive dyskinesia. Trans Am Neurol Assoc (1979) 0.75
Risk factors for drug-induced parkinsonism in tardive dyskinesia patients. J Clin Psychiatry (1988) 0.75
Letter: Deanol for tardive dyskinesia. N Engl J Med (1975) 0.75
Managing tardive dyskinesia. J Clin Psychiatry (1978) 0.75
Neuroleptic-potentiating effect of metyrosine. Am J Psychiatry (1979) 0.75
Theorizing about nurses' work lives: the personal and professional aftermath of living with healthcare 'reform'. Nurs Inq (1999) 0.75
Unexpected intracerebral pathology in older schizophrenic patients. Am J Psychiatry (1991) 0.75
Longitudinal assessment of older schizophrenic patients. Am J Psychiatry (1989) 0.75
The relationship between association responses and activity in the pyramidal tract. Electroencephalogr Clin Neurophysiol (1967) 0.75
Watch it: a method to assist and simplify record keeping. Plast Reconstr Surg (1980) 0.75
Neuroleptic-potentiating effect of alpha-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial. Acta Psychiatr Scand (1979) 0.75
Simultaneous metastatic epidermoid carcinoma and chronic granulocytic leukemia. Ann Plast Surg (1978) 0.75
SCH 23390 and psychosis. Lancet (1991) 0.75
Computed tomographic evaluation of patients with tardive dyskinesia. Schizophr Res (1991) 0.75
Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys. Psychopharmacology (Berl) (1987) 0.75
Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys. Prog Neuropsychopharmacol Biol Psychiatry (1990) 0.75
Tardive dyskinesia in an adolescent. Am J Psychiatry (1978) 0.75
Deanol in the management of involuntary movement disorders: a review. Dis Nerv Syst (1977) 0.75
Development and characterization of anti-spiroperidol antibodies. Biochem Pharmacol (1988) 0.75
Deanol in the treatment of tardive dyskinesia. Am J Psychiatry (1975) 0.75
Seven-year follow-up of tardive dyskinesia in Hungarian outpatients. Neuropsychopharmacology (1988) 0.75
Acute extrapyramidal syndromes in neuroleptic-treated elders: a pilot study. J Geriatr Psychiatry Neurol (1992) 0.75
Lack of platelet monoamine oxidase activity in Cebus monkeys (Cebus albifrons). Comp Biochem Physiol C (1989) 0.75
A longitudinal study of correlations among tardive dyskinesia, drug-induced parkinsonism, and psychosis. J Neuropsychiatry Clin Neurosci (1992) 0.75
New antipsychotics: preclinical and clinical research. Psychopharmacology (Berl) (1996) 0.75